Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 11/20 | 0.68 |
| ▸ | PFKFB4 | Q16877 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PFKFB3 | Q16875 | 4/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462164 | 0.86 | CMA1 (0.71) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL1259677 | 0.85 | PFKFB4 (0.64) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL2908164 | 0.84 | CMA1 (0.76) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL1259964 | 0.84 | PFKFB4 (0.62) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL16474294 | 0.83 | PFKFB4 (0.59) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL2912893 | 0.83 | CMA1 (0.82) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL4450959 | 0.83 | CMA1 (0.78) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL2912236 | 0.83 | CMA1 (0.82) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL1258761 | 0.82 | NPSR1 (0.69) | CMA1PFKFB4NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL2905421 | 0.81 | CMA1 (1.00) | CMA1PFKFB4PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-7399781-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-7071220-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | CMA1 3/4885PFKFB4 4092/4885NPSR1 88/4885 |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | CMA1 3/4885PFKFB4 4092/4885NPSR1 88/4885 |
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | REN, SERPINB1, CMA1 | CMA1 3/4885PFKFB4 3559/4885NPSR1 1683/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CMA1 313/4885PFKFB4 2964/4885NPSR1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.